Resources
Press
Alva10 announces partnership with Diaceutics joining DXRX platform to focus on value based reimbursement for diagnostics to increase utilization and access for targeted therapies
Mindera Health™ and WellDyne announce a definitive agreement to improve management of moderate-to-severe psoriasis patients
Transformational Pathway to US Payer System; Attributing US$1.4 Billion Health and Economic Benefit from geneType Breast Cancer
Alva10 partners with Diaceutics, joining DXRX platform to drive for value-based reimbursement models for the US
Publications
Mission Possible:
IQVIA Blog
Inside Precision Medicine
MedCity News
JOURNAL OF PRECISION MEDICINE
Journal Of Precision Medicine
MEDIUM
Mission Possible:
Mission Possible:
Mission Possible:
Morning Consult
PODCASTs
Episode 5 - IQVIA MedTech Business Insights
Surfing the NASH Tsunami
PIONEER INSTITUTE
Health Benefits Innovation
Precision Medicine podcast
Alzheimer Breakthrough Disillusionment: Confusion on FDA’s Approval of Expensive and Possibly Ineffective Drug
Value-Based Pricing in In Vitro Diagnostics with Lena Chaihorsky
S4-12 – Deep Dive: ICER Draft Report on Resmetirom and Obeticholic Acid for NASH
Delivering Better Patient Care includes Preemptive Strategies
Pharmacy Podcast Network
Then and Now: The Progress of Precision Medicine Diagnostics with Hannah Mamuszka and Lena Chaihorsky of Alva10
Lena Chaihorsky leads a panel discussion on the early adopters of diagnostics and the pilot programs that can get valuable diagnostics through the toughest period of early commercialization. Join us! Agenda here.
monday october 24, 2022
Jumpstarting a Diagnostic Product Launch via Innovative Pilots with Forward-Thinking Payers and Providers
AdvaMed
upcoming
and recent appearances
Episode 5 - IQVIA MedTech Business Insights: Value-Based Pricing in In Vitro Diagnostics with Lena Chaihorsky Listen to full podcast HERE.
thursday september 29, 2022
IQVIA MedTech Business Insights
medtech
upcoming
and recent appearances
Catch VP Lena Chaihorsky in conversation with Welldyne PBM’s Chief Medical Officer Nick Page about the innovative ways PBMs can engage with the diagnostic industry to support their own value propositions, and in so doing create an alternative market pathway for this critical category of healthcare tools. Watch HERE.
tuesday august 23, 2022
The Role of Alternative Payers in the Adoption of a Diagnostic
Cambridge Healthtech Institute
UPCOMING
AND RECENT APPEARANCES
Alva10 CEO Hannah Mamuszka and Erika Spaeth, PhD Director, Clinical Affairs, Phenogen Sciences discuss how a polygenic risk score for breast cancer can better assess risk for developing breast cancer than relying on BRCA status or family history alone. 85% of women who get breast cancer do not have a BRCA gene mutation and do not have family history of breast cancer. Watch HERE.
thursday june 23, 2022
Beyond BRCA: A Polygenic Risk Score to Identify Patients at Elevated Risk for Breast Cancer
Precision Medicine Leadership Summit
UPCOMING
AND RECENT APPEARANCES
Hannah Mamuszka and Blake Long, MD, of Alva10 join host Joe Selvaggi to discuss the role that Pharmacy Benefit Managers play in the high cost of prescription drugs in the US. Listen HERE.
april, 2022
Pharmacy Benefit Managers & the cost of prescription drugs in the us
alva10
UPCOMING
AND RECENT APPEARANCES
Lena Chaihorsky, Alva10’s VP of Payer Innovation reviews the hard truths about specialty drug efficacy rates and the ‘trial and error’ patterns of treating patients in the absence of diagnostics today, while offering solutions employers can implement today to decrease costs and improve outcomes. See the agenda HERE.
tuesday april 19, 2022
Ending Trial and Error Medicine: Why Your Drug Spend is So High
Pittsburgh Business Group
UPCOMING
AND RECENT APPEARANCES
Join Lena Chaihorsky for a discussion around prioritizing reimbursement as an early–stage biotech start-up. Learn about the historic mistakes made in the industry and learn how to set yourself up for success directly from a payer. Register HERE.
tuesday march 1, 2022
Why Payers Can Make or Break Your Product + How To Partner for Success
Biocom California
UPCOMING
AND RECENT APPEARANCES
Lena Chaihorsky joins a virtual panel discussion focused on understanding how to translate the national conversation around diagnostic importance into long term change for the diagnostic industry. See the agenda HERE.
tuesday september 21, 2021
COVID Momentum? Driving value and outcomes-based pricing in In Vitro Diagnostics
AdvaMed’s MedTech Conference
UPCOMING
AND RECENT APPEARANCES
Lena Chaihorsky joins a panel discussion led by the Get the Medications Right (GTMRx) Institute to raise awareness among employers about the low efficacy and high cost of specialty drugs. Check out a recap of the conversation HERE.
thursday september 9, 2021
Health 2021 Employer-Led Healthcare Symposium
Pittsburgh Business Group
UPCOMING
AND RECENT APPEARANCES
Explore where and why the status quo reimbursement model is not working for the diagnostics industry in a session with Lena Chaihorsky at the annual Q1 Diagnostic Coverage & Reimbursement Conference. Check out the annual Q1 conference series HERE.
Wednesday FEBRUARY 17, 2021
Flipping the Reimbursement Model
Q1 Productions
UPCOMING
AND RECENT APPEARANCES
Our VP of Payer Innovation Lena Chairhorsky spoke on a panel discussing reimbursement models for gene and cell therapies, and how diagnostics could be instrumental in proving their value and creating a sustainable model that allows developers and patients to be successful. Full agenda HERE
Wednesday December 9, 2020
INVEST Precision Medicine
MedCity
UPCOMING
AND RECENT APPEARANCES
Lena Chaihorsky discusses how to align incentives and develop tests that payers want to pay for. Check out the Video HERE
December 15th 12-1:30 PT, December 17th 10-11:30 PT, and December 18th 10-11:30 PT
Illumina Payer Summit
on-demand with live events
UPCOMING
AND RECENT APPEARANCES
UpCOMING & Recent appearances
Alva10 Videos
The pandemic has made everyone realize the importance of diagnostics in healthcare, but 8 months into the pandemic, we still lack the diagnostics we need to best manage Covid-19. How can we incentivize the development of the diagnostics we need to find disease, determine risk, and assess immunity? What are the regulatory barriers, and how can they be overcome? Who pays for these tests? What can we learn from Covid-19 for the next pandemic?
Diagnostics for Covid
How to Get What We Need
Diagnostic tests can be well validated, accepted in guidelines, and even reimbursed, yet they still don’t impact patient care. Why? Improper use, lack of physician understanding & support, lack of inclusion in coverage policies, inability to track all contribute to losing the potential impact of critical diagnostic tools. Software that highlights & streamlines decision making and provides information at the point of care allows for more efficient precision delivery of these tools.
Precision Medicine usually connotes use of diagnostics and other tools to optimize care in oncology, but really we should be considering development and use of these tools in every disease area. We will discuss the challenges around development and commercialization of Precision Medicine diagnostics for use in stroke and autoimmune diseases.
Hannah Mamuszka & Satabhisa Mukhopadhyay PhD, MS, Chief Scientific Officer & Founder, 4D Path discuss the potential for digital pathology to supplant IHC, PCR, FISH, & NGS in oncology, dramatically reducing cost & increasing patient access.
What is the potential for
Precision Medicine Outside of Oncolocy?
Precision Diagnostics 4D Path
Is it Possible to Obviate the Need for NGS Panels in Oncology with a Digital Solution?
How can Software Enable
Diagnostics to Impact Patient Care?
October 2019— Hannah Mamuszka, CEO, Alva10 on Rethinking the Companion Diagnostic Deal Structure to Benefit All Stakeholders
Companion Diagnostics Forum
Companion Diagnostics are Bad for Diagnostic Companies
PAYER-DRIVEN DIAGNOSTIC DEVELOPMENT: FLIPPING TODAY’S REIMBURSEMENT MODEL FOR COMMERCIALIZATION SUCCESS
Registration Required for Access.
Register
